Want to see HK:2297 full AI Analyst Report?
Top Page
Rainmed Medical Limited
(2297)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$0.19
▼(-26.92% Downside)
Action:Reiterated
Date:06/13/26
The score is held back primarily by weak financial performance (shrinking revenue, negative gross margin, and persistent cash burn), with only partial support from a relatively low-leverage balance sheet. Technicals are modestly constructive in the near term but not strong enough to offset the fundamental risks, and valuation provides limited support given the ongoing losses and no dividend yield.
Positive Factors
Low Current Leverage
The currently modest debt burden provides financial flexibility relative to a highly leveraged medical-device business. Lower leverage can reduce interest pressure, support continued investment, and give management more room to address operating challenges before balance-sheet constraints become binding.
Negative Factors
Sharp Revenue Contraction
Two consecutive years of substantial revenue contraction indicate weakening commercial scale and reduced demand conversion. Persistent top-line pressure can limit operating leverage, hinder product investment, and make it harder for the company to absorb fixed costs across its medical-device platform.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Current Leverage
The currently modest debt burden provides financial flexibility relative to a highly leveraged medical-device business. Lower leverage can reduce interest pressure, support continued investment, and give management more room to address operating challenges before balance-sheet constraints become binding.
Read all positive factors
Rainmed Medical Limited (2297) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$269.06M
Dividend YieldN/A
Average Volume (3M)102.03K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue Growth4.35%
EPS Growth43.23%
CountryHK
Employees210
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,401,358,800
10 Day Avg. Volume50,000
30 Day Avg. Volume102,033
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.88
Price to Sales (P/S)16.34
P/FCF Ratio-3.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Rainmed Medical Limited Business Overview & Revenue Model
Company Description
Rainmed Medical Limited is a medical technology firm specializing in the creation, development, and market launch of advanced systems that utilize coronary angiography to assess fractional flow reserve (FFR) and the index of microvascular resistan...
How the Company Makes Money
Rainmed Medical Limited primarily makes money by selling medical devices and related consumables to healthcare providers (e.g., hospitals and clinics) and/or through medical-device distribution channels. Key revenue drivers typically include (i) s...
Rainmed Medical Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 19.18M | 39.82M | 73.22M | 83.60M | 81.20M |
| Gross Profit | 9.04M | 23.87M | 48.55M | 69.82M | 69.03M |
| EBITDA | -67.39M | -82.98M | -93.54M | -1.33B | -623.97M |
| Net Income | -77.08M | -113.50M | -115.83M | -1.35B | -633.64M |
Balance Sheet | |||||
| Total Assets | 545.73M | 463.06M | 573.31M | 690.33M | 640.19M |
| Cash, Cash Equivalents and Short-Term Investments | 153.35M | 205.55M | 335.28M | 578.96M | 559.14M |
| Total Debt | 24.83M | 25.58M | 20.00M | 28.98M | 1.38B |
| Total Liabilities | 187.59M | 53.15M | 53.30M | 71.69M | 1.41B |
| Stockholders Equity | 357.54M | 407.00M | 515.05M | 618.64M | -774.48M |
Cash Flow | |||||
| Free Cash Flow | -79.69M | -138.10M | -235.27M | -141.04M | -103.95M |
| Operating Cash Flow | -76.40M | -84.31M | -124.29M | -111.22M | -72.83M |
| Investing Cash Flow | 7.24M | 6.31M | 180.29M | -515.74M | -27.98M |
| Financing Cash Flow | 30.15M | 723.00K | -15.88M | 120.73M | 633.85M |
Rainmed Medical Limited Technical Analysis
Negative
0.26
Price Trends
0.21
Negative
0.23
Negative
0.25
Negative
Market Momentum
>-0.01
Negative
36.67
Neutral
56.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2297, the sentiment is Negative. The current price of 0.26 is above the 20-day moving average (MA) of 0.20, above the 50-day MA of 0.21, and above the 200-day MA of 0.25, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 36.67 is Neutral, neither overbought nor oversold. The STOCH value of 56.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2297.
Rainmed Medical Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | HK$442.27M | 4.51 | 13.95% | 6.76% | 10.95% | 9.26% | |
63 Neutral | HK$1.96B | 14.05 | 8.16% | ― | 20.65% | 127.07% | |
59 Neutral | HK$2.86B | 28.37 | 4.06% | ― | 94.80% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$269.06M | -3.36 | -19.46% | ― | 4.35% | 43.23% | |
45 Neutral | HK$538.03M | -0.99 | -28.24% | ― | -38.15% | 25.70% | |
41 Neutral | HK$335.75M | -2.15 | -12.45% | ― | ― | ― |
* Healthcare Sector Average
HK:2297
Rainmed Medical Limited
0.19
-0.15
-43.53%
HK:6669
Acotec Scientific Holdings Limited
6.13
-9.00
-59.48%
HK:1612
Vincent Medical Holdings Limited
0.68
-0.45
-40.09%
HK:2216
Broncus Holding Corp.
0.62
-2.92
-82.49%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
6.70
-2.36
-26.05%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.31
-2.80
-68.17%
Rainmed Medical Limited Corporate Events
Rainmed Medical reshapes board with director resignation and new appointment
Sep 4, 2026
Rainmed Medical Limited has announced the resignation of non-executive director Wang Lin, effective 4 September 2026, as he steps down to devote more time to other commitments. The board stated there is no disagreement associated with his departur...
Rainmed Medical Details Board and Committee Structure
Sep 4, 2026
Rainmed Medical Limited has disclosed the composition of its board of directors, naming chairman Huo Yunfei and detailing a mix of executive, non-executive and independent non-executive directors. The announcement underscores the company’s g...
Rainmed narrows interim loss as revenue and margins improve
Aug 31, 2026
Rainmed Medical Limited reported a 41.3% year-on-year rise in revenue to RMB14.7 million for the six months ended June 30, 2026, with gross profit up 82.4% and margin improving to 63.2%. Despite the stronger top-line and better profitability, the ...
Rainmed Medical Sets Board Meeting to Approve 2026 Interim Results and Consider Dividend
Aug 13, 2026
Rainmed Medical Limited has scheduled a board meeting for August 31, 2026, to review and approve the unaudited interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consider whether to reco...
Rainmed Medical Wins Unanimous Backing for AGM Resolutions and Capital Mandates
Jun 29, 2026
Rainmed Medical Limited reported that all resolutions at its 29 June 2026 annual general meeting were approved by shareholders through a poll, including adoption of the audited consolidated financial statements for the year ended 31 December 2025....
Rainmed Medical Reshuffles Joint Company Secretary and Compliance Representative
Jun 8, 2026
Rainmed Medical Limited announced a change in its senior corporate governance roles, with joint company secretary and authorised representative Ms. Chu Cheuk Ting resigning effective June 8, 2026, citing other work arrangements and confirming no d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.